These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38025284)

  • 1. Comparative study of efficacy and safety of cetirizine and bilastine in patients of chronic spontaneous urticaria: Open-label, randomized, parallel-group study.
    Sinha VV; Kalikar MV; Mukhi JI; Giradkar AB; Sontakke S
    Perspect Clin Res; 2023; 14(4):180-186. PubMed ID: 38025284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: a randomized, double-blind, 6-week trial.
    Dakhale GN; Shinde AT; Mahatme MS; Hiware SK; Mishra DB; Mukhi JI; Salve AM
    Int J Dermatol; 2014 May; 53(5):643-9. PubMed ID: 24320728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial.
    Podder I; Das A; Ghosh S; Biswas D; Sengupta S; Chowdhury SN
    Dermatol Ther; 2020 Nov; 33(6):e13946. PubMed ID: 32618048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis.
    Sastre J; Mullol J; Valero A; Valiente R;
    Curr Med Res Opin; 2012 Jan; 28(1):121-30. PubMed ID: 22077106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study.
    Serra E; Campo C; Novák Z; Majorek-Olechowska B; Pulka G; García-Bea A; Labeaga L
    J Dermatolog Treat; 2020 May; 31(3):270-278. PubMed ID: 30835579
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
    Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
    Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study.
    Zuberbier T; Oanta A; Bogacka E; Medina I; Wesel F; Uhl P; Antépara I; Jáuregui I; Valiente R;
    Allergy; 2010 Apr; 65(4):516-28. PubMed ID: 19860762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases.
    Yagami A; Furue M; Togawa M; Saito A; Hide M
    J Dermatol; 2017 Apr; 44(4):375-385. PubMed ID: 27862227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study.
    Hide M; Yagami A; Togawa M; Saito A; Furue M
    Allergol Int; 2017 Apr; 66(2):317-325. PubMed ID: 27599913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study.
    Kuna P; Bachert C; Nowacki Z; van Cauwenberge P; Agache I; Fouquert L; Roger A; Sologuren A; Valiente R;
    Clin Exp Allergy; 2009 Sep; 39(9):1338-47. PubMed ID: 19438584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans.
    Church MK
    Inflamm Res; 2011 Dec; 60(12):1107-12. PubMed ID: 21874559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Efficacy, Safety and Cost-effectiveness of Rupatadine and Olopatadine in Patients of Chronic Spontaneous Urticaria: A Randomized, Double-blind, Comparative, Parallel Group Trial.
    Dakhale GN; Wankhede SS; Mahatme MS; Hiware SK; Mishra DB; Dudhgaonkar SS
    Indian J Dermatol; 2016; 61(1):63-9. PubMed ID: 26955097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilastine in Refractory Chronic Spontaneous Urticaria: Disease Control and Cytokine Modulation in an Open-label Prospective Study.
    De A; Singh S; Chakraborty D; Sarda A; Godse K
    Indian J Dermatol; 2024; 69(2):132-136. PubMed ID: 38841225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bilastine: in allergic rhinitis and urticaria.
    Carter NJ
    Drugs; 2012 Jun; 72(9):1257-69. PubMed ID: 22686617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparative, Three-Arm, Randomized Clinical Trial to Evaluate the Effectiveness and Tolerability of Bilastine vs Fexofenadine vs Levocetirizine at the Standard Dose and Bilastine vs Fexofenadine at Higher Than the Standard Dose (Up-Dosing) vs Levocetirizine and Hydroxyzine (in Combination) in Patients with Chronic Spontaneous Urticaria.
    Shah B; Dhoot D; Choudhary A; Jangid N; Mistry D; Shah S; Kamat S; Barkate H
    Clin Cosmet Investig Dermatol; 2022; 15():261-270. PubMed ID: 35221703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Bilastine on Symptoms of Allergic Rhinitis and Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Abdelshafy AM; Abdallah SY; Hassan AF; Mohamed HA; Kamal NM; Ali ST; Abdelhaleem IA
    Am J Rhinol Allergy; 2022 Sep; 36(5):684-694. PubMed ID: 35593100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Indian Experience of Switchover to Bilastine 40 mg/day in CSU Patient Refractory to Other Antihistamines at Double Dose.
    De A; Shah B; Banodkar PD; Dhoot D; Chitnis K; Barkate H
    Indian J Dermatol; 2023; 68(6):674-677. PubMed ID: 38371575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-Life Experience of Efficacy and Safety of Bilastine in the Refractory Cases of Chronic Spontaneous Urticaria and its Effect on the Quality of Life of Patients.
    De A; Godse K; Dhoot D; Sarda A
    Indian J Dermatol; 2021; 66(2):159-164. PubMed ID: 34188271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Prospective Randomized Non-Blinded Study of Safety and Efficacy of Bilastine Up-Dosing (40 mg) Versus Combination of Bilastine 20 mg With Levocetirizine 5 mg in the Treatment of Chronic Spontaneous Urticaria.
    Sneha B; Narasimhan M; Durai PCT; Ramakrishnan R
    Indian J Dermatol; 2024; 69(3):226-231. PubMed ID: 39119328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine.
    Wang XY; Lim-Jurado M; Prepageran N; Tantilipikorn P; Wang de Y
    Ther Clin Risk Manag; 2016; 12():585-97. PubMed ID: 27110120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.